{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.00","upperLimit":"3.00","value":"2.00"},{"groupId":"OG001","lowerLimit":"1.00","upperLimit":"6.00","value":"2.00"},{"groupId":"OG002","lowerLimit":"1.00","upperLimit":"3.00","value":"2.00"},{"groupId":"OG003","lowerLimit":"1.00","upperLimit":"10.00","value":"1.50"}]}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.00","upperLimit":"2.00","value":"1.50"},{"groupId":"OG001","lowerLimit":"0.98","upperLimit":"3.00","value":"1.55"},{"groupId":"OG002","lowerLimit":"1.00","upperLimit":"3.00","value":"1.75"},{"groupId":"OG003","lowerLimit":"1.00","upperLimit":"3.00","value":"1.50"}]}],"title":"Day 21"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"15"}],"units":"Participants"}],"description":"tmax is defined as the time of occurenceof Cmax. Blood samples for PK analysis of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.","dispersionType":"Full Range","groups":[{"description":"Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.","id":"OG000","title":"Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.","id":"OG001","title":"Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.","id":"OG002","title":"Part D: Dabrafenib 75 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.","id":"OG003","title":"Part D: Dabrafenib 150 mg + Trametinib 2 mg"}],"paramType":"MEDIAN","populationDescription":"PK Population. Only participants available at the indicated timepoints were analyzed.","reportingStatus":"POSTED","timeFrame":"Day 1 and Day 21","title":"Part D (Analyte=GSK2118436): Tmax of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib","type":"PRIMARY","unitOfMeasure":"Hours"}